milrinone การใช้

• Phosphodiesterase inhibitors such as milrinone are sometimes utilized in severe cardiomyopathy.
• Milrinone, sold as Primacor, was approved in 1987.
• Two of the patients in the study died, both of whom were given milrinone.
• Milrinone is a phosphodiesterase-3 inhibitor.
• Milrinone decreases survival in heart failure.
• Sanofi-Synthelabo Inc ., which markets milrinone in the United States, funded the study.
• The study involved 949 patients given either a dummy drug or a 48-hour milrinone infusion.
• Milrinone has been used before to treat young patients who developed low cardiac output syndrome after surgery.
• In 2012 they also identified Wenxin Keli and Milrinone as potential pharmacological therapies for the Brugada syndrome.
• She said Milrinone, another drug approved for acute heart failure, costs about $ 375 per vial.
• The average length of hospitalization did not differ significantly _ six days for milrinone and seven days for placebo.
• Milrinone use following cardiac surgery has been under some debate because of the potential increase risk of postoperative atrial arrhythmias.
• The 3, 4'- Bipyridine derivatives inamrinone and milrinone are used occasionally for short term treatment of congestive heart failure.
• Milrinone allows stimulation of cardiac function independently of ?-adrenergic receptors which appear to be down-regulated in those with heart failure.
• Also, by causing the buildup of cAMP in the myocardium, Milrinone increases contractile force, heart rate and the extent of relaxation.
• The study divided 238 patients at 31 hospitals into three groups that were given either a placebo or a low or high dose of milrinone.
• Dr . Ann Bolger, an American Heart Association spokeswoman, said patients studied were generally less sick than those who typically would be given milrinone.
• The study shows " there really isn't any advantage " to giving milrinone to patients who are not acutely ill, Bolger said.
• The company's Web site warns that the drug may cause irregular heartbeats, and says milrinone should be stopped if blood pressure falls too low.
• Sixty-day death rates _ 10.3 percent in milrinone patients and 8.9 percent in placebo patients _ also did not differ significantly.